Xtant Medical Holdings, Inc. revised earnings guidance for the year 2023. For the year, the company raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company?s prior guidance of $75 million to $77 million. The revised guidance range represents annual revenue growth of approximately 52% to 57% compared to full year 2022 revenue, and includes contributions from the Surgalign transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8173 USD | +2.16% | +0.11% | -27.67% |
04-30 | Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds | CI |
04-01 | Xtant Medical Files $150 Million Mixed Shelf; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.67% | 104M | |
+8.29% | 124B | |
-5.61% | 11.02B | |
+4.83% | 8.88B | |
+39.60% | 5.45B | |
-22.04% | 4.74B | |
+8.39% | 3.44B | |
-6.28% | 2.84B | |
-10.23% | 2.15B | |
-5.99% | 2.11B |
- Stock Market
- Equities
- XTNT Stock
- News Xtant Medical Holdings, Inc.
- Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023